197 related articles for article (PubMed ID: 34133324)
21. Spatial maps of prostate cancer transcriptomes reveal an unexplored landscape of heterogeneity.
Berglund E; Maaskola J; Schultz N; Friedrich S; Marklund M; Bergenstråhle J; Tarish F; Tanoglidi A; Vickovic S; Larsson L; Salmén F; Ogris C; Wallenborg K; Lagergren J; Ståhl P; Sonnhammer E; Helleday T; Lundeberg J
Nat Commun; 2018 Jun; 9(1):2419. PubMed ID: 29925878
[TBL] [Abstract][Full Text] [Related]
22. High expression of PDGFR-β in prostate cancer stroma is independently associated with clinical and biochemical prostate cancer recurrence.
Nordby Y; Richardsen E; Rakaee M; Ness N; Donnem T; Patel HR; Busund LT; Bremnes RM; Andersen S
Sci Rep; 2017 Feb; 7():43378. PubMed ID: 28233816
[TBL] [Abstract][Full Text] [Related]
23. Multicenter clinical validation of PITX2 methylation as a prostate specific antigen recurrence predictor in patients with post-radical prostatectomy prostate cancer.
Bañez LL; Sun L; van Leenders GJ; Wheeler TM; Bangma CH; Freedland SJ; Ittmann MM; Lark AL; Madden JF; Hartman A; Weiss G; Castaños-Vélez E
J Urol; 2010 Jul; 184(1):149-56. PubMed ID: 20478579
[TBL] [Abstract][Full Text] [Related]
24. Gene expression signature of Gleason score is associated with prostate cancer outcomes in a radical prostatectomy cohort.
Jhun MA; Geybels MS; Wright JL; Kolb S; April C; Bibikova M; Ostrander EA; Fan JB; Feng Z; Stanford JL
Oncotarget; 2017 Jun; 8(26):43035-43047. PubMed ID: 28496006
[TBL] [Abstract][Full Text] [Related]
25. Integrated bioinformatics analysis identified COL11A1 as an immune infiltrates correlated prognosticator in pancreatic adenocarcinoma.
Zheng X; Liu X; Zheng H; Wang H; Hong D
Int Immunopharmacol; 2021 Jan; 90():106982. PubMed ID: 33129696
[TBL] [Abstract][Full Text] [Related]
26. Identification of key DNA methylation-driven genes in prostate adenocarcinoma: an integrative analysis of TCGA methylation data.
Xu N; Wu YP; Ke ZB; Liang YC; Cai H; Su WT; Tao X; Chen SH; Zheng QS; Wei Y; Xue XY
J Transl Med; 2019 Sep; 17(1):311. PubMed ID: 31533842
[TBL] [Abstract][Full Text] [Related]
27. Patient-Level DNA Damage and Repair Pathway Profiles and Prognosis After Prostatectomy for High-Risk Prostate Cancer.
Evans JR; Zhao SG; Chang SL; Tomlins SA; Erho N; Sboner A; Schiewer MJ; Spratt DE; Kothari V; Klein EA; Den RB; Dicker AP; Karnes RJ; Yu X; Nguyen PL; Rubin MA; de Bono J; Knudsen KE; Davicioni E; Feng FY
JAMA Oncol; 2016 Apr; 2(4):471-80. PubMed ID: 26746117
[TBL] [Abstract][Full Text] [Related]
28. Identification and Characterization of Circulating Tumor Cells in Men Who have Undergone Prostatectomy for Clinically Localized, High Risk Prostate Cancer.
Friedlander TW; Welty C; Anantharaman A; Schonhoft JD; Jendrisak A; Lee J; Li P; Hough J; Stromlund A; Edwards M; Sangar S; Kobayashi Y; Simko J; Farrokhian N; Lindquist K; Greene S; Ontiveros P; Graf R; Rodriquez A; Suraneni M; Wang Y; Landers M; Carroll P; Cooperberg MR; Dittamore R; Paris PL
J Urol; 2019 Oct; 202(4):732-741. PubMed ID: 31216253
[TBL] [Abstract][Full Text] [Related]
29. Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors.
Rochow H; Jung M; Weickmann S; Ralla B; Stephan C; Elezkurtaj S; Kilic E; Zhao Z; Jung K; Fendler A; Franz A
Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33105568
[TBL] [Abstract][Full Text] [Related]
30. Identification of recurrence marker associated with immune infiltration in prostate cancer with radical resection and build prognostic nomogram.
Rui X; Shao S; Wang L; Leng J
BMC Cancer; 2019 Dec; 19(1):1179. PubMed ID: 31795990
[TBL] [Abstract][Full Text] [Related]
31. The University of California, San Francisco Cancer of the Prostate Risk Assessment score: a straightforward and reliable preoperative predictor of disease recurrence after radical prostatectomy.
Cooperberg MR; Pasta DJ; Elkin EP; Litwin MS; Latini DM; Du Chane J; Carroll PR
J Urol; 2005 Jun; 173(6):1938-42. PubMed ID: 15879786
[TBL] [Abstract][Full Text] [Related]
32. Expression changes in the stroma of prostate cancer predict subsequent relapse.
Jia Z; Rahmatpanah FB; Chen X; Lernhardt W; Wang Y; Xia XQ; Sawyers A; Sutton M; McClelland M; Mercola D
PLoS One; 2012; 7(8):e41371. PubMed ID: 22870216
[TBL] [Abstract][Full Text] [Related]
33. Importance of tumor location in patients with high preoperative prostate specific antigen levels (greater than 20 ng/ml) treated with radical prostatectomy.
Magheli A; Rais-Bahrami S; Peck HJ; Walsh PC; Epstein JI; Trock BJ; Gonzalgo ML
J Urol; 2007 Oct; 178(4 Pt 1):1311-5. PubMed ID: 17698095
[TBL] [Abstract][Full Text] [Related]
34. Epigenetic silencing of MEIS2 in prostate cancer recurrence.
Nørgaard M; Haldrup C; Bjerre MT; Høyer S; Ulhøi B; Borre M; Sørensen KD
Clin Epigenetics; 2019 Oct; 11(1):147. PubMed ID: 31640805
[TBL] [Abstract][Full Text] [Related]
35. Predicting the Clinical Outcome of Lung Adenocarcinoma Using a Novel Gene Pair Signature Related to RNA-Binding Protein.
Meng L; He X; Zhang X; Zhang X; Wei Y; Wu B; Li J; Xiao Y
Biomed Res Int; 2020; 2020():8896511. PubMed ID: 33195699
[TBL] [Abstract][Full Text] [Related]
36. Reduction in expression of the benign AR transcriptome is a hallmark of localised prostate cancer progression.
Stuchbery R; Macintyre G; Cmero M; Harewood LM; Peters JS; Costello AJ; Hovens CM; Corcoran NM
Oncotarget; 2016 May; 7(21):31384-92. PubMed ID: 27120785
[TBL] [Abstract][Full Text] [Related]
37. Receptor activator of nuclear factor-kappaB ligand (RANKL) as a novel prognostic marker in prostate carcinoma.
Pérez-Martínez FC; Alonso V; Sarasa JL; Manzarbeitia F; Vela-Navarrete R; Calahorra FJ; Esbrit P
Histol Histopathol; 2008 Jun; 23(6):709-15. PubMed ID: 18366009
[TBL] [Abstract][Full Text] [Related]
38. The relationship between the extent of surgical margin positivity and prostate specific antigen recurrence in radical prostatectomy specimens.
Marks RA; Koch MO; Lopez-Beltran A; Montironi R; Juliar BE; Cheng L
Hum Pathol; 2007 Aug; 38(8):1207-11. PubMed ID: 17490720
[TBL] [Abstract][Full Text] [Related]
39. Bcl-2 is significantly overexpressed in localized radio-recurrent prostate carcinoma, compared with localized radio-naive prostate carcinoma.
Rosser CJ; Reyes AO; Vakar-Lopez F; Levy LB; Kuban DA; Hoover DC; Lee AK; Pisters LL
Int J Radiat Oncol Biol Phys; 2003 May; 56(1):1-6. PubMed ID: 12694817
[TBL] [Abstract][Full Text] [Related]
40. Developing an immune-related gene prognostic index associated with progression and providing new insights into the tumor immune microenvironment of prostate cancer.
Feng D; Zhang F; Li D; Shi X; Xiong Q; Wei Q; Yang L
Immunology; 2022 Jun; 166(2):197-209. PubMed ID: 35271752
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
